2008 - 2010 Pathogenesis of non-alcoholic steatohepatitis (NASH) and establishment of diagnostics and treatment
2008 - 2010 Molecular basis for persistent hepatitis virus infection and development of eradication of the viruses
2008 - 2010 Impact of HCV-associated metabolic abnormalities on liver disease progression
2005 - 2009 C型肝炎ウイルスによる肝発癌機構の解明
2005 - 2009 Mechanism of hepatocarcinogenesis in hepatitis C
2003 - 2008 HIV感染症に合併する肝疾患に関する研究
2003 - 2008 Liver diseases accompanying HIV infection
Show all
Papers (59):
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology. 2019
Long-term risk of malignancy in branch duct intraductal papillary mucinous neoplasms. Gastroenterology. 2019
Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism. Nat Commun. 2019. 10. 947
Impact of AAV2 and hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection. Clin Cancer Res. 2019
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci Rep. 2019. 9. 10663